mTOR as a therapeutic target in patients with gastric cancer.
about
New advances in targeted gastric cancer treatmentThe Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal CancerCurrent Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical ApplicationmTOR, a new potential target for chronic pain and opioid-induced tolerance and hyperalgesiaThe critical role of Akt in cardiovascular functionOpioid receptor-triggered spinal mTORC1 activation contributes to morphine tolerance and hyperalgesiaGenetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform.A polymorphism (rs2295080) in mTOR promoter region and its association with gastric cancer in a Chinese populationCombination of carbonic anhydrase inhibitor, acetazolamide, and sulforaphane, reduces the viability and growth of bronchial carcinoid cell lines.Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats.mTOR inhibition in management of advanced breast cancer.Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in micemTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in micemTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injuryPhase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma.Blocking mammalian target of rapamycin alleviates bladder hyperactivity and pain in rats with cystitis.Blocking mammalian target of rapamycin (mTOR) improves neuropathic pain evoked by spinal cord injury.Impacts of the mTOR gene polymorphisms rs2536 and rs2295080 on breast cancer risk in the Chinese population.DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathwayTargeted therapy for gastric cancer.Current and Future Treatment Strategies for Patients with Advanced Hepatocellular Carcinoma: Role of mTOR Inhibition.Recent advances and future trends in the targeted therapy of metastatic gastric cancer.The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.Celecoxib sensitizes gastric cancer to rapamycin via inhibition of the Cbl-b-regulated PI3K/Akt pathway.Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation.Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling.Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ-opioid receptor.Dramatic antitumor effects of the dual mTORC1 and mTORC2 inhibitor AZD2014 in hepatocellular carcinoma.Celastrol induces cell cycle arrest by MicroRNA-21-mTOR-mediated inhibition p27 protein degradation in gastric cancer.Targeting mTORC2 component rictor inhibits cell proliferation and promotes apoptosis in gastric cancer.The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance.Rapamycin inhibits the invasive ability of thyroid cancer cells by down-regulating the expression of VEGF-C in vitro.Angiogenesis inhibitors in early development for gastric cancer.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway.Involvement of pro-inflammation signal pathway in inhibitory effects of rapamycin on oxaliplatin-induced neuropathic pain.miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway.Knockdown of RAI14 suppresses the progression of gastric cancerWhole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations
P2860
Q26738548-F5E8F1F6-B431-40A8-B060-EC5045765E31Q26744721-412A3203-B1BB-4309-B581-CAA90B153470Q26765941-44D26656-6880-4691-B472-CB858A952A9FQ28081540-BBAC0A45-F3E7-408A-A236-C85E94124382Q28083829-E93C252F-AE13-4EC9-BB9B-FFA097ED7751Q28576512-69B28096-58B9-4954-A9DB-4AE28599FBE1Q33903687-02B085B3-96BB-446F-B795-718F50E524A2Q34653205-D69BB6A8-467B-4C02-AEBF-6F112E8A8F79Q34911416-4C12D61F-E6AB-4774-9650-A40212B6448CQ35874744-31758868-E35F-48BE-9216-CD12572D7CECQ36228145-71DD625A-04B1-4449-86C1-F21B8B903C81Q36544718-B19EF978-57FA-4D4B-9A0E-9BBF972866ABQ36580462-E54322BF-7425-4B28-A42A-C8C9052ED590Q36843926-FD00D487-66D8-4946-8A9E-12D336452537Q36977421-E4F0623D-B7EF-4733-A9EE-FA3BB580E044Q37375064-B645E169-935A-44D8-871D-C1B26A45F62FQ37585446-56EF67FE-5826-4E36-AA25-33C1D223B4DEQ37629003-3DAA5F9A-1F49-4135-BA5B-6FD2DB89FF8BQ37652251-8B76E681-6FBF-4BEC-854E-15C58AFC508CQ38007119-8052D840-7105-42EF-8122-61925AE55C7EQ38155511-A51C6A05-B2D9-48C5-88B3-1EB6612A04C8Q38199128-A351F347-1DAC-4E0D-90AE-7AD9D3D9C5D6Q38772498-C886A5CC-059C-4D45-9098-8769206B8E77Q38907631-E0416986-6EE7-4369-8A0B-DE850C070091Q39096573-15DF79C9-1B5D-4054-9138-F8428FFD4DC0Q39147611-B281CA4D-9D1D-4F6E-BE4C-413471906E87Q40323078-79731D0E-20D9-4EBB-90E3-793F4B954BBDQ42027870-405709A9-C58D-418A-B994-A8E4DD5DA8D2Q42061952-2CFEA3E1-65F1-4E7F-82B3-F94B7E0A594AQ42068002-5677CF02-BFF9-47CF-B41A-4178DD7D2049Q44802535-1F3F626D-9606-48CF-B446-F6FC149C93A6Q46393415-4BD4B123-8A1D-47D7-AA89-9D32DB236821Q47996955-293DA373-A1E5-40CB-9BBF-453EF1218402Q48522177-89D3CEDD-6C0E-4B67-A3AD-F4560421BFC6Q52627434-3402D5CF-0ECF-4E48-92DB-4341BC0FDEDFQ53314337-C6E99B65-29A6-4ED5-B182-6C64A4E108D7Q57817288-B777544B-7A57-4FD3-9287-A2757FD733F0Q58118126-978AD956-F6AA-40B8-ABC6-B2A49C23B63F
P2860
mTOR as a therapeutic target in patients with gastric cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
mTOR as a therapeutic target in patients with gastric cancer.
@en
mTOR as a therapeutic target in patients with gastric cancer.
@nl
type
label
mTOR as a therapeutic target in patients with gastric cancer.
@en
mTOR as a therapeutic target in patients with gastric cancer.
@nl
prefLabel
mTOR as a therapeutic target in patients with gastric cancer.
@en
mTOR as a therapeutic target in patients with gastric cancer.
@nl
P2093
P2860
P356
P1476
mTOR as a therapeutic target in patients with gastric cancer.
@en
P2093
Atsushi Ohtsu
Michel Ducreux
Salah-Eddin Al-Batran
P2860
P304
P356
10.1002/IJC.26396
P577
2011-10-05T00:00:00Z